WCG Unveils Results from 2023 Global Site Relationship Benchmark Survey Report
WCG released results from the 2023 CenterWatch Global Site Relationship Benchmark Survey Report. The results show how more than 3,600 representatives from clinical trial sites around the world rate their sponsor and clinical research organization (CRO) relationships as the industry is adjusting to a post-pandemic world.
New to the report this year is the ability for sponsors to evaluate how the CRO that acts on their behalf impacts their site ratings.
Site respondents were asked to rank the overall reputation of 77 sponsors and 34 CROs and rate the relative importance of performance related attributes. They were then requested to identify the organizations they had worked with most during the past two years and rate the performance of those organizations against the attributes.
Both sponsors and CROs received the highest performance scores for the quality of their communication with site staff and their responsiveness to site inquiries, as well as for being professional, organized, and knowledgeable. Areas of improvement based on site recommendations included feedback from sites and study participants/participant groups in protocol design and support for initiatives to help sites build stronger relationships with study volunteers. Recommendations for improvement for CROs included greater efficiency in contract and budget negotiation and receiving ongoing feedback from sites. Sites also recommended more flexibility among both sponsors and CROs to modify budgets.
WCG CenterWatch included many of the same performance attributes in its 2017, 2019, and 2021 surveys so that longitudinal comparisons can be made between those results, and trends evaluated. An in-depth general report, which includes the 2023 sponsor and CRO rankings, is available at https://www.centerwatch.com/products/category/1061-benchmark-reports.
Reference
WCG Unveils Results from 2023 Global Site Relationship Benchmark Survey Report. (2023 May, 24). Cision PR Newswire.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
